Clinical Trials
31 trialsAdjuvant WIDER
Novartis
BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder
University of Illinois at Chicago
ADEPT
Dana-Farber Cancer Institute
CARABELA
Spanish Breast Cancer Research Group
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
University of Michigan Rogel Cancer Center
e3
SWOG Cancer Research Network
BYLieve
Novartis
RWE About QOL and Compliance of Patients With OFS in China
Fudan University
POP-ELA
Gustave Roussy, Cancer Campus, Grand Paris
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
Fudan University
FACILE
Fondazione Sandro Pitigliani
PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate
Seoul National University Hospital
Detect V / CHEVENDO (Chemo vs. Endo)
University of Ulm
TP-II
Palleos Healthcare GmbH
Density Lowering Effect of "OFS Add on to TMX"(DELFINO Trial)
Seoul National University Hospital
COMPLEEMENT-1
Novartis
PEER
National Taiwan University Hospital
ASPAIT
First Affiliated Hospital, Sun Yat-Sen University
BOOSTER
Japan Breast Cancer Research Group
LEO
Asan Medical Center
Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer"
Takeda
A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC
Samsung Medical Center
NEOADAPT
Midwestern Regional Medical Center
NeoChAI
National Cancer Center, Korea
Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer
Fudan University
Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: "QOL Survey in Premenopausal Breast Cancer Patients"
Takeda
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Dana-Farber Cancer Institute
Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey "Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)"
Takeda
Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer
National Cancer Institute (NCI)
Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer
National Cancer Institute (NCI)
Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer
University of Washington